ReviewTranslational breast cancer research : a journal focusing on translational research in breast cancer2026
Chinese expert consensus on endocrine therapy for breast cancer (2026 edition).
Review in Translational breast cancer research : a journal focusing on translational research in breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endocrine therapy (ET) is the primary treatment for hormone receptor (HR)-positive breast cancer. Based on the 2023 expert consensus, the Chinese Consensus Group on Breast Cancer Endocrine Therapy updated this consensus by integrating clinical research data and practical experiences. Methods: (I) Establishment of expert group: the expert group consists of experts from departments such as medical oncology, breast surgery, and pathology. (II) Literature search: mainly conducted in English databases (such as PubMed, Embase, and Cochrane Library) with a search cutoff date of Sep 30 Results: The 2026 consensus updated clinical research data on ET for both early and advanced breast cancer, defined the eligible population for neoadjuvant ET, and clarified the application of adjuvant cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in moderate and high-risk patients. For advanced breast cancer, the consensus optimized the treatment strategy of first-line ET plus CDK4/6i, and recommended preferred post-CDK4/6i regimens for patients with distinct clinic-pathological characteristics. It also provides clear recommendations on the indication, optimal timing, and methodology of genetic testing. Conclusions: This consensus may provide clinical guidance for the standardized application of ET, thereby facilitating precise and individualized treatment for HR-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.